Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

146.30
+0.71000.49%
Post-market: 146.300.00000.00%19:53 EDT
Volume:4.54M
Turnover:660.59M
Market Cap:181.51B
PE:-55.95
High:146.35
Open:144.00
Low:142.94
Close:145.59
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.88
T/O Rate:0.37%
Dividend:3.22
Dividend Rate:2.20%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.34
PE(LYR):21.58

Loading ...

Gilead Sciences Expands Lenacapavir Access to 14 Countries

MT Newswires Live
·
Yesterday

Gilead announces agreement with PAHO for lenacapavir access

TIPRANKS
·
Yesterday

Gilead: Explores Opportunities with Brazilian Health Ministry to Advance Ministry’s Goal of Enabling Local Production of Lenacapavir

THOMSON REUTERS
·
Yesterday

Gilead: Agreement Establishes Regional Pathway Through Pan American Health Organization's Regional Revolving Funds

THOMSON REUTERS
·
Yesterday

Gilead: Co & Paho Announce Partnership to Accelerate Access to Twice-Yearly Lenacapavir for Hiv Prevention Across Latin America & Caribbean

THOMSON REUTERS
·
Yesterday

Gilead, PAHO Agree on HIV Prevention Drug Access in Latin America, Caribbean

Reuters
·
Yesterday

Gilead: to Continue Exploring Opportunities to Work with Paho to Support Country Readiness & Scale-up of Long-Acting Hiv Prevention Access

THOMSON REUTERS
·
Yesterday

Gilead Exec Says Weekly Oral Hiv Prevention Drug Expected to Launch in First Quarter of 2027 - Conf Call

THOMSON REUTERS
·
Yesterday

Gilead Exec Says Hiv Market Growth Should Normalize to 2%-3% Within Next Couple of Quarters - Conf Call

THOMSON REUTERS
·
Yesterday

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Moderna Inc. Stock Rallies 5.4%, Outperforms Peers

Dow Jones
·
Sep 12

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

TIPRANKS
·
Sep 11

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Sep 09

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Sep 09

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Sep 09